Evidence map›Paper›PMID 40052001›Full record

ArticlePatient preference and adherence2025

Group-Based Trajectory Modeling to Identify Patterns and Predictors of Adherence to Oral Endocrine Therapies in Underserved Population of Greater Houston Area.

Yashvi Patel, Hasan Alsaedi, Zahra Majd, Issra Altaie, Sama Rahimi, Bilqees Fatima, Onyebuchi Ononogbu, Susan Abughosh, Meghana V Trivedi

Abstract read
In one paragraph

Article in Patient preference and adherence, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yashvi Patel *Department of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy, Houston, TX, USA.
Hasan Alsaedi *Department of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy, Houston, TX, USA.
Zahra MajdDepartment of Pharmaceutical Health Outcomes and Policy, University of Houston College of Pharmacy, Houston, TX, USA.
Issra AltaieDepartment of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy, Houston, TX, USA.
Sama RahimiDepartment of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy, Houston, TX, USA.
Bilqees FatimaDepartment of Pharmaceutical Health Outcomes and Policy, University of Houston College of Pharmacy, Houston, TX, USA.
Onyebuchi OnonogbuDepartment of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy, Houston, TX, USA.
Susan AbughoshDepartment of Pharmaceutical Health Outcomes and Policy, University of Houston College of Pharmacy, Houston, TX, USA.
Meghana V TrivediDepartment of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy, Houston, TX, USA.ORCID 0000-0002-0585-5580

Funding

Testing a Digital Therapeutic for Smoking Cessation among Hispanic Persons who SmokeU54MD015946 · NIMHD · UNIVERSITY OF HOUSTON · PI MICHAEL J. ZVOLENSKY · 2020 to 2026
$22.0M
FOXA1 inhibitors to overcome endocrine resistance in ER+ breast cancerP20CA221729 · NCI · BAYLOR COLLEGE OF MEDICINE · PI CHOW, DIANA S-L., MATZUK, MARTIN M. · 2018 to 2021
$1.0M
NCI NIH HHS P20 CA221729NIMHD NIH HHS U54 MD015946
6 · The paper itself

Abstract

Background: Poor adherence to oral endocrine therapy (OET) is a significant problem among patients with hormone receptor-positive breast cancer as it results in higher risk of recurrence and mortality. Non-adherence to OET is prevalent among underserved patients, often attributable to socioeconomic factors and limited healthcare access. We evaluated OET adherence patterns over time using group-based trajectory modeling (GBTM) and identified predictors of suboptimal adherence trajectory among patients seen at Harris Health System, serving underserved patients in Houston, Texas. Methods: A single-center, retrospective study was conducted from October 2019 through December 2020. OET adherence was measured using proportion of days covered (PDC). A logistic GBTM was conducted using 2-5 adherence groups considering the Bayesian information criteria, clinical relevance, and a 5% minimum membership requirement. Multinomial logistic regression was used to assess the predictors of non-adherence trajectories. Results: Among 496 patients, majority were Hispanic (62.50%) or African American (15.12%) and <65 years of age (82.66%). Four distinct adherence trajectories were identified: consistent high adherence (41.4%); constant PDC at ~0.6 (32.6%); rapid decline (14.6%); low adherence with gradual decline (11.5%). African Americans had higher likelihood of having low adherence with gradual decline [odds ratio (OR): 2.462 (confidence interval (CI): 1.1149-5.276), p=0.0205]. Patients with diabetes were more likely to have constant PDC at ~0.6 [OR: 1.714 (CI: 1.042-2.820), p=0.0338]. Longer time (4 or greater years) on therapy predicted low adherence with gradual decline [OR: 2.463 (CI: 1.266-4.793), p=0.008) and constant PDC at ~0.6 (OR: 1.966 (CI: 1.141-3.388), p=0.0149] trajectories. Conclusion: The identified predictors, including comorbidities like diabetes, African American descent, and longer OET treatment are crucial considerations when developing patient-centered interventions to enhance OET adherence among underserved populations. These insights can guide the implementation of initiatives such as mobile health applications, community-based educational programs, and financial aid efforts.

Indexed as

breast cancergroup-based trajectory modelingmedication adherenceminorityoral endocrine therapyunderserved

Identifiers

PMID40052001
PMCPMC11882467

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.